Press Releases Puma Biotechnology, Inc.

Equities

PBYI

US74587V1070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
4.96 ^USD	+0.20%		+1.64%	+14.55%

Mar. 20	Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise	MT
Mar. 20	Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Puma Biotech: Q1 Earnings Snapshot	May. 02	AQ
Puma Biotechnology Reports First Quarter Financial Results	May. 02	BU
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results	Apr. 18	BU
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(4)	Apr. 04	AQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	Apr. 03	BU
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	Mar. 20	BU
Puma Biotechnology : Corporate Presentation	Mar. 06	PU
Puma Biotech: Q4 Earnings Snapshot	Feb. 29	AQ
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 29	BU
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	Feb. 27	BU
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference	Feb. 22	BU
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results	Feb. 15	BU
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer	Feb. 13	BU
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference	Jan. 11	BU
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	Dec. 11	BU
HER2-mutant Non-Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 22	AQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	Nov. 06	BU
Puma Biotech: Q3 Earnings Snapshot	Nov. 02	AQ
Puma Biotechnology Reports Third Quarter 2023 Financial Results	Nov. 02	BU
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results	23-10-19	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Puma Biotechnology, Inc.

Equities

PBYI

US74587V1070

Press Releases

Filters